Remarkably, MaR1 conferred protection against chemotherapy-induced peripheral neuropathy (CIPN) by inducing GPR37L1-dependent upregulation of surface KCNJ10 expression and KCNJ10-mediated K+ currents in SGCs. Here, KCNJ10 is linked to peripheral neuropathy.